CARM
|Carisma Therapeutics Inc.
NASDAQ
USD 0.45
-0.10|-17.62%
Current Price
USD 0.45
Change
USD -0.10 (-17.62%)
P/E Ratio
Dividend Yield
Market Cap
7.65M
Volume
12.52M
Open
USD 0.54
Previous Close
USD 0.55
52-Week High
USD 1.90
52-Week Low
USD 0.14
About Carisma Therapeutics Inc.
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidate includes CT-2401, which is in preclinical trail for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothel...
Sector:Healthcare
Industry:Biotechnology
CEO:Mr. Steven Kelly
Employees:46
Headquarters:Philadelphia, USA
Website:www.carismatx.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|---|---|---|---|
| Mar 2, 2023 | Mar 7, 2023 | Mar 10, 2023 | USD 1.53 | |
| Mar 2, 2023 | Mar 7, 2023 | Mar 8, 2023 | USD 0.36 |
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions